The layoffs of thousands of miners in Chiatura, Georgia, ought to be big news in a country of under four million people. But ...

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

WEHI researchers have made a huge leap forward in the fight against Parkinson's disease, solving a decades-long mystery that paves the way for development of new drugs to treat the condition.